Pharmafile Logo
Pharmafocus logo
Advanced Search

Merck Serono

Showing 12 posts of 72 posts found.

Merck Serono asks EMEA to re-think Erbitux rejection

July 30, 2009
Research and Development, Sales and Marketing Cancer, EMEA, Erbitux, Europe, Merck Serono

Merck Serono is to appeal against the European rejection of Erbitux as a lung cancer treatment.Erbitux has been rejected as …

News

NICE rejects Erbitux in head and neck cancer

June 24, 2009
Research and Development, Sales and Marketing Erbitux, Merck Serono, NICE

News

Working Life: Kevin Crowe

June 23, 2009
Sales and Marketing Merck Serono, WL, sales force effectiveness

How did you find your way into your current role?I have worked for several years in the Canadian pharmaceutical industry …

Feature

Merck Serono breast cancer vaccine enters phase III

June 22, 2009
Research and Development Cancer, Merck Serono, Stimuvax, vaccines

Merck Serono is to begin a global phase III study for its therapeutic cancer vaccine Stimuvax in patients with advanced, …

News

Recession hits Merck KGaA profits

April 29, 2009
Sales and Marketing Merck Serono

Merck KGaA saw its profits fell through the floor for the first quarter this year due to a combination of …

News

Merck Serono launches Kuvan in Europe

April 24, 2009
Sales and Marketing Kuvan, Merck Serono, PKU

Kuvan, the first treatment for two rare neurological disorders, has been launched in the UK, France and Germany.Merck Serono’s drug …

News

Merck Serono sets up biotech fund

March 24, 2009
Research and Development Merck Serono, biotech

Merck Serono has set up a venture capital fund to invest in emerging biotech companies working in its core therapy …

News

Merck Serono’s multiple sclerosis drug on track for filing

January 23, 2009
Research and Development, Sales and Marketing MS, Merck Serono

Cladribine, a new oral treatment for multiple sclerosis is on track for a mid-2009 filing after the release of encouraging …

News

The Pharmafocus Interview: Elmar Schnee

January 6, 2009
Sales and Marketing EU, Germany, IQWIG, Merck Serono, cost-effectiveness

Germany's Merck has the kind of business model that investors warm to during times of recession. The company is the …

Feature

Merck Serono takes lead role in antibody partnership

September 11, 2008
Research and Development Merck Serono

Merck Serono has agreed to take on full responsibility for developing a promising antibody from its partner ZymoGenetics. The German …

News

Erbitux set for first line treatment of colorectal cancer

June 5, 2008
Sales and Marketing Cancer, Merck Serono

Merck Serono's Erbitux looks set for approval in Europe as a first-line colon cancer treatment. Approved four years ago as …

News

Merck to buy Serono for $13 billion

September 22, 2006
Sales and Marketing Merck Serono

German pharma company Merck is to acquire Serono for $13.5 billion, creating one of Europes largest bio-pharmaceutical technology companies.The new …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024